Market Overview:
The global eye infection drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of eye infections, rising awareness about eye care, and technological advancements in the field of ophthalmology. Based on type, levofloxacin is expected to be the fastest-growing segment during the forecast period. This growth can be attributed to its high efficacy and safety profile. Levofloxacin is also available in both oral and injectable formulations, which makes it easier for physicians to prescribe it as per patient needs. Based on application, conjunctivitis is expected to be the largest segment during the forecast period owing to its high prevalence across all regions globally. Conjunctivitis often leads to other serious complications such as keratitis (inflammation of cornea), iritis (inflammation of iris), and glaucoma (increased pressure within eyeball that may damage optic nerve).
Product Definition:
Eye infection drugs are used to treat infections of the eye. They may be used to treat a bacterial, viral, or fungal infection.
Levofloxacin:
Levofloxacin, also known as Lomefloxacin, is a fluoroquinolone antibiotic. It works by inhibiting the bacterial enzymes that make DNA and RNA. The drug has excellent antibacterial activity against gram-positive and negative bacteria including anaerobic organisms. Levofloxacin ophthalmic solution (liquid) is used to treat bacterial infections in the eye; it may be used in combination with other antibiotics or for extended therapy.
Ciprofloxacin:
Ciprofloxacin, also known as Cipro, is an antibiotic drug and is used to treat bacterial infections of the cornea. It works by killing the bacteria that causes the infection. The ophthalmic (eye) dose usually ranges from 0.3 to 0.6 mg/kg every 8 hours; however, higher doses are sometimes necessary in serious cases where vision loss is expected within a few days or weeks depending on type and location of infection.
Application Insights:
The other application segment held the largest share of over 50.0% in 2017. Other common infections include corneal ulcers, styes, eyelid infection, and others. The usage of antibiotic ointments for the treatment of eyelid infection is a well-established practice across the globe due to its effectiveness and low cost as compared to surgery or medical drops used for this purpose. However, there are few side effects associated with this drug such as allergic reaction leading to swelling around the eyes which requires immediate medical attention in case it occurs soon after application of ointment or drops on affected area.
The usage rate for antibiotics pertaining to conjunctivitis is relatively higher than that pertaining to any other disease category owing to its availability throughout pharmacies.
Regional Analysis:
In 2017, North America dominated the global market owing to the rising incidence of infectious diseases and increasing prevalence of chronic conditions. According to a study published in The Journal of Infectious Diseases in 2016, around 1 out of 4 people in U.S. will get an eye infection at some point during their lifetime.
Asia Pacific is expected to grow at fastest rate over the forecast period due high unmet needs regarding various infectious diseases prevalent across this region including cat-scratch disease, chlamydia infections & trachoma among others which result into increased demand for effective drugs with reduced side effects or toxicity levels as compared levofloxacin.
Growth Factors:
- Increasing incidence of eye infections: The increasing incidence of eye infections is one of the key growth drivers for the global Eye Infection Drugs market. This is mainly due to the changing lifestyles and growing pollution levels across the world.
- Rising awareness about eye infection treatments: There is a rising awareness among people about various treatments for different types of eye infections. This is driving demand for Eye Infection Drugs products globally.
- Technological advancements in Eye Infection Drugs products: The technological advancements in Eye Infection Drugs products are helping to improve their efficacy and safety profile, which is resulting in an increase in their demand worldwide.
- Growing aging population: The growing aging population across the globe is leading to an increase in incidences of age-related eye diseases, such as cataracts and glaucoma, thereby fueling demand for Eye Infection Drugs products globally .5) Emerging markets offer significant growth potential: The emerging markets offer significant growth potential for the global Eye Infection Drugs market owing to rapid economic development and rising disposable incomes there
Scope Of The Report
Report Attributes
Report Details
Report Title
Eye Infection Drugs Market Research Report
By Type
Levofloxacin, Ciprofloxacin, Others,
By Application
Conjunctivitis, Styes, Eyelid Infection, Others,
By Companies
Novartis, Allergan, Bausch Health, Santen Pharmaceutical, Lupin Pharmaceuticals, Apotex, Akorn
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Eye Infection Drugs Market Report Segments:
The global Eye Infection Drugs market is segmented on the basis of:
Types
Levofloxacin, Ciprofloxacin, Others,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Conjunctivitis, Styes, Eyelid Infection, Others,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Allergan
- Bausch Health
- Santen Pharmaceutical
- Lupin Pharmaceuticals
- Apotex
- Akorn
Highlights of The Eye Infection Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Levofloxacin
- Ciprofloxacin
- Others
- By Application:
- Conjunctivitis
- Styes
- Eyelid Infection
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Eye Infection Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Eye infection drugs are medications used to treat eye infections. These medications can be prescribed by a doctor, and they may include antibiotics, antiviral agents, or antifungal agents.
Some of the key players operating in the eye infection drugs market are Novartis, Allergan, Bausch Health, Santen Pharmaceutical, Lupin Pharmaceuticals, Apotex, Akorn.
The eye infection drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Eye Infection Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Eye Infection Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Eye Infection Drugs Market - Supply Chain
4.5. Global Eye Infection Drugs Market Forecast
4.5.1. Eye Infection Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Eye Infection Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Eye Infection Drugs Market Absolute $ Opportunity
5. Global Eye Infection Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Eye Infection Drugs Market Size and Volume Forecast by Type
5.3.1. Levofloxacin
5.3.2. Ciprofloxacin
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Eye Infection Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Eye Infection Drugs Market Size and Volume Forecast by Application
6.3.1. Conjunctivitis
6.3.2. Styes
6.3.3. Eyelid Infection
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Eye Infection Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Eye Infection Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Eye Infection Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Eye Infection Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Eye Infection Drugs Demand Share Forecast, 2019-2026
9. North America Eye Infection Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Eye Infection Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Eye Infection Drugs Market Size and Volume Forecast by Application
9.4.1. Conjunctivitis
9.4.2. Styes
9.4.3. Eyelid Infection
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Eye Infection Drugs Market Size and Volume Forecast by Type
9.7.1. Levofloxacin
9.7.2. Ciprofloxacin
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Eye Infection Drugs Demand Share Forecast, 2019-2026
10. Latin America Eye Infection Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Eye Infection Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Eye Infection Drugs Market Size and Volume Forecast by Application
10.4.1. Conjunctivitis
10.4.2. Styes
10.4.3. Eyelid Infection
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Eye Infection Drugs Market Size and Volume Forecast by Type
10.7.1. Levofloxacin
10.7.2. Ciprofloxacin
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Eye Infection Drugs Demand Share Forecast, 2019-2026
11. Europe Eye Infection Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Eye Infection Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Eye Infection Drugs Market Size and Volume Forecast by Application
11.4.1. Conjunctivitis
11.4.2. Styes
11.4.3. Eyelid Infection
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Eye Infection Drugs Market Size and Volume Forecast by Type
11.7.1. Levofloxacin
11.7.2. Ciprofloxacin
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Eye Infection Drugs Demand Share, 2019-2026
12. Asia Pacific Eye Infection Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Eye Infection Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Eye Infection Drugs Market Size and Volume Forecast by Application
12.4.1. Conjunctivitis
12.4.2. Styes
12.4.3. Eyelid Infection
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Eye Infection Drugs Market Size and Volume Forecast by Type
12.7.1. Levofloxacin
12.7.2. Ciprofloxacin
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Eye Infection Drugs Demand Share, 2019-2026
13. Middle East & Africa Eye Infection Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Eye Infection Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Eye Infection Drugs Market Size and Volume Forecast by Application
13.4.1. Conjunctivitis
13.4.2. Styes
13.4.3. Eyelid Infection
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Eye Infection Drugs Market Size and Volume Forecast by Type
13.7.1. Levofloxacin
13.7.2. Ciprofloxacin
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Eye Infection Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Eye Infection Drugs Market: Market Share Analysis
14.2. Eye Infection Drugs Distributors and Customers
14.3. Eye Infection Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Allergan
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bausch Health
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Santen Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Lupin Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Apotex
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Akorn
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook